We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

75 hedge funds and large institutions have $328M invested in KalVista Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

10% more funds holding

Funds holding: 68 → 75 (+7)

5.1% more ownership

Funds ownership: 80.61% → 85.72% (+5.1%)

18% less capital invested

Capital invested by funds: $398M → $328M (-$70.4M)

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
75
Holders Change
+7
Holders Change %
+10.29%
% of All Funds
1.63%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.09%
New
24
Increased
20
Reduced
18
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.6M
2
EAM
Eventide Asset Management
Massachusetts
+$14.1M
3
DM
Deerfield Management
New York
+$13.3M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$10.7M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.66M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$41.2M
2
VMI
VHCP Management III
New York
-$7.8M
3
VMI
VHCP Management II
New York
-$4.61M
4
Renaissance Technologies
Renaissance Technologies
New York
-$4.58M
5
SHI
SV Health Investors
Massachusetts
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
76
RA Capital Management
Massachusetts
– -$41.2M -1,441,070 Closed
Renaissance Technologies
77
Renaissance Technologies
New York
– -$4.58M -159,929 Closed
O
78
OrbiMed
New York
– -$2.59M -90,500 Closed
FI
79
Fosun International
China
– -$2.03M -72,606 Closed
BCM
80
Bridgeway Capital Management
Texas
– -$1.72M -60,000 Closed
LCM
81
Laurion Capital Management
New York
– -$1.69M -58,871 Closed
WCM
82
Wedge Capital Management
North Carolina
– -$1.31M -45,905 Closed
Marshall Wace
83
Marshall Wace
United Kingdom
– -$843K -29,452 Closed
TEE
84
Tibra Equities Europe
United Kingdom
– -$727K -25,401 Closed
EI
85
EAM Investors
California
– -$682K -23,830 Closed
ECM
86
ExodusPoint Capital Management
New York
– -$666K -23,253 Closed
BCM
87
BlueCrest Capital Management
Jersey
– -$304K -10,620 Closed
GCP
88
GSA Capital Partners
United Kingdom
– -$211K -7,371 Closed
MWNA
89
Marshall Wace North America
New York
– -$175K -6,126 Closed
Federated Hermes
90
Federated Hermes
Pennsylvania
– -$14K -491 Closed
DWA
91
Dorsey Wright & Associates
California
– -$12K -433 Closed
AG
92
Advisor Group
Arizona
– -$1K -50 Closed
1 2 3
4

KALV Hedge Fund Activity: Q2 2019 in Review

75 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2019, worth a combined $328M — down 18% from $398M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new KALV positions and 17 closed out — a net gain of 7 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $15.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $41.2M sold.

  • 75 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2019, up from 68 in Q1 2019.
  • Funds reported $328M of KalVista Pharmaceuticals stock for Q2 2019, down 18% quarter-over-quarter.
  • 24 funds opened new KalVista Pharmaceuticals positions in Q2 2019 and 17 closed out, a net change of +7 holders.
  • The largest KalVista Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $15.6M added.
  • The largest KalVista Pharmaceuticals seller in Q2 2019 was RA Capital Management, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2019.